Escherichia coli serogroup O107/O117 lipopolysaccharide binds and neutralizes Shiga toxin 2

被引:18
作者
Gamage, SD [1 ]
McGannon, CM [1 ]
Weiss, AA [1 ]
机构
[1] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA
关键词
D O I
10.1128/JB.186.16.5506-5512.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The AB(5) toxin Shiga toxin 2 (Stx2) has been implicated as a major virulence factor of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains in the progression of intestinal disease to more severe systemic complications. Here, we demonstrate that supernatant from a normal E. coli isolate, FI-29, neutralizes the effect of Stx2, but not the related Stx1, on Vero cells. Biochemical characterization of the neutralizing activity identified the lipopolysaccharide (LPS) of FI-29, a serogroup O107/O117 strain, as the toxin-neutralizing component. LPSs from FI-29 as well as from type strains E. coli O107 and E. coli O117 were able bind Stx2 but not Stx1, indicating that the mechanism of toxin neutralization may involve inhibition of the interaction between Stx2 and the Gb(3) receptor on Vero cells.
引用
收藏
页码:5506 / 5512
页数:7
相关论文
共 43 条
[1]   Distribution of core oligosaccharide types in lipopolysaccharides from Escherichia coli [J].
Amor, K ;
Heinrichs, DE ;
Frirdich, E ;
Ziebell, K ;
Johnson, RP ;
Whitfield, C .
INFECTION AND IMMUNITY, 2000, 68 (03) :1116-1124
[2]   A PHASE-I STUDY OF CHEMICALLY SYNTHESIZED VEROTOXIN (SHIGA-LIKE TOXIN) PK-TRISACCHARIDE RECEPTORS ATTACHED TO CHROMOSORB FOR PREVENTING HEMOLYTIC-UREMIC SYNDROME [J].
ARMSTRONG, GD ;
ROWE, PC ;
GOODYER, P ;
ORRBINE, E ;
KLASSEN, TP ;
WELLS, G ;
MACKENZIE, A ;
LIOR, H ;
BLANCHARD, C ;
AUCLAIR, F ;
THOMPSON, B ;
RAFTER, DJ ;
MCLAINE, PN .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :1042-1045
[3]   Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans [J].
Boerlin, P ;
McEwen, SA ;
Boerlin-Petzold, F ;
Wilson, JB ;
Johnson, RP ;
Gyles, CL .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) :497-503
[4]   ANTIBODIES TO ESCHERICHIA-COLI O157 IN PATIENTS WITH HEMORRHAGIC COLITIS AND HEMOLYTIC UREMIC SYNDROME [J].
CHART, H ;
SCOTLAND, SM ;
SMITH, HR ;
ROWE, B .
JOURNAL OF CLINICAL PATHOLOGY, 1989, 42 (09) :973-976
[5]   SITE OF ACTION OF A VERO TOXIN (VT2) FROM ESCHERICHIA-COLI O157-H7 AND OF SHIGA TOXIN ON EUKARYOTIC RIBOSOMES - RNA N-GLYCOSIDASE ACTIVITY OF THE TOXINS [J].
ENDO, Y ;
TSURUGI, K ;
YUTSUDO, T ;
TAKEDA, Y ;
OGASAWARA, T ;
IGARASHI, K .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 171 (1-2) :45-50
[6]   Structure and function of lipopolysaccharides [J].
Erridge, C ;
Bennett-Guerrero, E ;
Poxton, IR .
MICROBES AND INFECTION, 2002, 4 (08) :837-851
[7]   Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin [J].
Gamage, SD ;
Strasser, JE ;
Chalk, CL ;
Weiss, AA .
INFECTION AND IMMUNITY, 2003, 71 (06) :3107-3115
[8]  
HEAD SC, 1991, J BIOL CHEM, V266, P3617
[9]  
Ito Hiroshi, 2002, Japanese Journal of Antibiotics, V55, P203
[10]   Responses of human intestinal microvascular endothelial cells to shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis [J].
Jacewicz, MS ;
Acheson, DWK ;
Binion, DG ;
West, GA ;
Lincicome, LL ;
Fiocchi, C ;
Keusch, GT .
INFECTION AND IMMUNITY, 1999, 67 (03) :1439-1444